scholarly journals Evaluation of Serum Tumor Markers Variation, Following The Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Sorush Niknamian
Keyword(s):  
Thyroid Cancer ◽  
Tumor Markers ◽  
Repeated Measures ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Serum Tumor Markers ◽  
Third Stage ◽  
Serological Studies ◽  
The One ◽  
Radioactive Iodine 131

Introduction: Radioactive iodine is the effective therapy in thyroid cancer. The aim of this study is to evaluate the serum tumor markers in patients under the therapy with radioactive iodine 131. Material and Methods: 45 cases of female patients aged 16-60 years with thyroid cancer surgery referred to the nuclear medicine department of Nemazi hospital for (iodine treatment after surgery) were selected. The selection was on the basis of interviewing and information of patients is consent forms. Only patients with thyroid cancer and referred for the first time without any other diseases were chosen for this study. The selected patients were prescribed a dose of 150 m Ci of I-131. From each patient, 4 mL of chelated serum for serological studies on tumor markers and 2 mL of oxalated serum for spectrophotometry studies on cell death were used in three stages. The first stage before the iodine therapy, the second stage, after 48 hours, and the third stage, 30 days after radioiodine therapy were studied and the results were evaluated by the one-way repeated measures ANOVA test. Results: According to the results of dependent paired T-Test, AFP, in the periods before, 48 hours and 1 month after radioiodine therapy, respectively were 3.46 ± 1.21 and 3.74 ± 1.37 and 3.76 ± 1.25 (p <0.0005). About CA 19-9 in the periods before, 48 hours and one month after radioiodine therapy, the results were 9.30 ± 6.32, 9.95 ± 6.92 (p = 0.040) and 11.26 ± 7.49 (p <0.0005) respectively. About CEA, the results were 1.60 ± 0.60, 1.47 ± 0.55 and 2.23 ± 0.69 (p <0.0005), respectively. In the case of tumor marker CA 15-3 results were 15.53 ± 6.48 and 1.60 ± 0.60 and 15.68 ± 6.52 (p = 0.014), respectively and in the case of ALP, results were 124.22 ± 5 and 122.2 ± 6 and 116.7 ± 7 (p <0.0005), respectively. Conclusion: According to the same studies and the acquired results, it can be concluded that the tumor markers CEA and CA19-9 are more acceptable and sustainable for monitoring the malignancy and progressive disease in patients with thyroid cancer. The decreasing ALP is normal and transient. The increase of AFP and CA15-3 is not even statistically reliable. It is recommended that the period of iodine therapy and falsely elevated tumor markers can be informed to the doctor, during the gastrointestinal studies in patients with thyroid cancer, in order to prevent wrong decisions on the treatment process.

scholarly journals Evaluation of Serum Tumor Markers Variation, following the Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Sorush Niknamian
Keyword(s):  
Thyroid Cancer ◽  
Tumor Markers ◽  
Repeated Measures ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Serum Tumor Markers ◽  
Third Stage ◽  
Serological Studies ◽  
The One ◽  
Radioactive Iodine 131

Introduction: Radioactive iodine is the effective therapy in thyroid cancer. The aim of this study is to evaluate the serum tumor markers in patients under the therapy with radioactive iodine 131. Material and methods: 45 cases of female patients aged 16-60 years with thyroid cancer surgery referred to the nuclear medicine department of Nemazi hospital for (iodine treatment after surgery) were selected. The selection was on the basis of interviewing and information of patients is consent forms. Only patients with thyroid cancer and referred for the first time without any other diseases were chosen for this study. The selected patients were prescribed a dose of 150mCi of I-131.From each patient, 4 mL of chelated serum for serological studies on tumor markers and 2 mL of oxalated serum for spectrophotometry studies on cell death were used in three stages. The first stage before the iodine therapy, the second stage, after 48 hours, and the third stage, 30 days after radioiodine therapy were studied and the results were evaluated by the one-way repeated measures ANOVA test. Results: according to the results of dependent paired T-Test, AFP, in the periods before, 48 hours and 1 month after radioiodine therapy, respectively were 3.46±1.21 and 3.74±1.37 and 3.76±1.25 (p <0.0005). About CA 19-9 in the periods before, 48 hours and one month after radioiodine therapy, the results were 9.30±6.32, 9.95±6.92 (p = 0.040) and 11.26±7.49 (p <0.0005) respectively. About CEA, the results were 1.60±0.60, 1.47±0.55 and 2.23±0.69 (p <0.0005), respectively. In the case of tumor marker CA 15-3 results were 15.53±6.48 and 1.60±0.60 and 15.68±6.52 (p = 0.014), respectively and in the case of ALP, results were 124.22±5 and 122.2±6 and 116.7±7 (p <0.0005), respectively. Conclusion: According to the same studies and the acquired results, it can be concluded that the tumor markers CEA and CA19-9 are more acceptable and sustainable for monitoring the malignancy and progressive disease in patients with thyroid cancer. The decreasing ALP is normal and transient. The increase of AFP and CA15-3 is not even statistically reliable. It is recommended that the period of iodine therapy and falsely elevated tumor markers can be informed to the doctor, during the gastrointestinal studies in patients with thyroid cancer, in order to prevent wrong decisions on the treatment process.

scholarly journals Concentration of Thyroglobulin and Thyroglobulin-Specific Autoantibodies in Patients With Differentiated Thyroid Cancer After Treatment With Radioactive Iodine 131

2011 ◽  
Vol 42 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Olgica B. Vrndic ◽  
Svetlana B. Savin ◽  
Ljiljana C. Mijatovic ◽  
Aleksandar A. Djukic ◽  
Ilija D. Jeftic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Iodine 131 ◽  
Radioactive Iodine 131

scholarly journals Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?

2016 ◽  
Vol 60 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Marcelo Cruzick de Souza ◽  
Denise P. Momesso ◽  
Fernanda Vaisman ◽  
Leonardo Vieira Neto ◽  
Rosangela Aparecida Gomes Martins ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Iodine 131 ◽  
Radioactive Iodine 131

scholarly journals Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment

Medicine ◽  
2015 ◽  
Vol 94 (45) ◽  
pp. e2016 ◽  
Author(s):  
R.A. Werner ◽  
J.S. Schmid ◽  
D.O. Muegge ◽  
K. Lückerath ◽  
T. Higuchi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Prognostic Value ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Serum Tumor Markers

Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases

2007 ◽  
Vol 5 (6) ◽  
pp. 631-640 ◽  
Author(s):  
Jacqueline Jonklaas
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
Adjuvant Therapy ◽  
Cancer Cells ◽  
Differentiated Thyroid Cancer ◽  
Sodium Iodide ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Sodium Iodide Symporter ◽  
Thyroid Cancer Cells

Normal thyrocytes and thyroid cancer cells are characterized by possession of a sodium iodide symporter. Radioiodine administration is a unique and powerful means of treating differentiated thyroid cancer because of the ability of thyroid cancer cells to concentrate beta-emitting radiolabeled iodine. Several manipulations, such as iodine depletion and thyroid hormone-stimulating hormone elevation, are used to enhance uptake of radiolabeled iodine by tumor cells. Adjuvant radioiodine therapy, given to patients without evidence of residual disease, enhances the sensitivity of subsequent surveillance and may decrease recurrence rates and mortality. However, its exact role in the management of low-risk patients merits further investigation. In contrast, radioactive iodine therapy used in patients with residual or metastatic disease clearly improves outcomes. Several studies show decreased recurrence and mortality rates in patients treated with radioiodine compared with those not receiving radioactive iodine. Adverse events from radioiodine therapy include salivary gland dysfunction, bone marrow suppression, and reproductive disturbances. Side effects of radioiodine therapy are generally greater when higher activities of radioiodine are used and may be transient or permanent. Secondary malignancies also may occur after radioiodine therapy. These side effects must be weighed against potential benefits, especially when radioactive iodine is used as adjuvant therapy. Stimulation of the expression of the sodium iodide symporter, or its introduction de novo into nonthyroid cells, is promising in treating poorly differentiated thyroid cancer and nonthyroid malignancies, respectively.

scholarly journals Protein and Lipid Concentrations in Patients with Differentiated Thyroid Cancer Treated with Radioactive Iodine-131 / Koncentracija Proteina I Lipida Kod Pacijenata Sa Diferentovanim Karcinomom Štitaste Žlezde Koji Su Lečeni Radioaktivnim Jodom-131

2014 ◽  
Vol 15 (4) ◽  
pp. 197-203 ◽  
Author(s):  
Olgica Mihaljevic ◽  
Snezana Radivojevic ◽  
Svetlana Djukic ◽  
Ljiljana Mijatovic Teodorovic ◽  
Irena Kostic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Protein Concentration ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Overt Hypothyroidism ◽  
Healthy Control ◽  
Iodine 131 ◽  
The Mean ◽  
Older Subjects ◽  
Radioactive Iodine 131

ABSTRACT Short-term, overt hypothyroidism in patients with differentiated thyroid cancer (DTC) before radioiodine (131-I) therapy might be accompanied by a number of metabolic changes, including altered protein and lipid metabolism. Protein concentrations and their relationship to lipids in the serum of DTC patients have not been fully elucidated. The aim of our study was to evaluate the protein and lipid concentrations in 24 DTC patients before and 3 and 7 days after 131-I therapy compared with those of 20 healthy control subjects. After radioiodine therapy, the mean protein concentration (78.71 ± 6.71 g/L vs. 87.16 ± 6.04 g/L; p = 0.003) and cholesterol level (8.12 ± 2.13 mmol/L vs. 8.84 ± 2.09 mmol/L; p = 0.001) were lower 3 days after therapy; this persisted up to 7 days after therapy, whereas triglyceride concentrations were higher 3 days after therapy (2.44 ± 1.07 mmol/L vs. 2.26 ± 1.08 mmol/L; p = 0.041) and returned towards the pretreatment values at 7 days after 131-I therapy. There was an indirect correlation between the protein and triglyceride concentrations 3 days after 131-I therapy in patients over 50 years old (Spearman’s r = - 0.583, p = 0.048) but not in patients under 50 years old (Pearson’s r = - 0.277, p = 0.384). Radioiodine therapy of DTC patients led to decreased serum protein and cholesterol concentrations, accompanied by increased triglyceride levels; these changes were especially evident in older subjects with metastases.

Sign in / Sign up

Export Citation Format

Share Document